They are funded through until at least mid next year by which time they will have results of three phase 2 trials. The most important milestone this year is the interim data release for SNT 5505 in myelofibrosis - and a presentation at ASH in December. Spec buy and hold until then in my opinion.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
6.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $97.64M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| SNT (ASX) Chart |
Day chart unavailable